T-Space at The University of Toronto Libraries >
School of Graduate Studies - Theses >
Please use this identifier to cite or link to this item:
|Title: ||Evaluation of Pharmacotherapy for Common Medical Conditions in Pregnancy|
|Authors: ||Ebrahimi, Neda|
|Advisor: ||Koren, Gideon|
|Department: ||Pharmaceutical Sciences|
|Keywords: ||Pharmaceutical Sciences|
|Issue Date: ||7-Dec-2011|
|Abstract: ||Purpose Two new scales, CORECTS and PUQE-24 are introduced and validated, and the
safety and effectiveness of Proctofoam-HC® in pregnancy is demonstrated.
Method 315 of Motherisk NVP patients provided information on five clinical parameters
as well as PUQE scores. 28 patients visiting a proctologist were graded for the severity of
anal conditions by a proctologist before administering CORECTS. Pre and postnatal
interviews were conducted with 204 pregnant women prescribed Proctofoam-HC®.
Results Strong correlations were found between the following:
PUQE-24 scores and parameters of well-being, hospitalization, and multivitamin intake;
bleeding and pain components of CORECTS and the proctologist’s grade.There was no
significant difference between mean birth weight of Proctofoam-HC® treated and
comparison groups. There was a significant reduction in all symptoms of hemorrhoids.
Conclusion PUQE-24 and CORECTS are the first validated scales used to assess the
severity of NVP and hemorrhoids. Proctofoam-HC® is safe and effective for use in
|Appears in Collections:||Master|
Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.